Does Cosentyx Affect Inactivated Vaccines?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not impair immune responses to inactivated vaccines. Clinical studies show patients on Cosentyx mount effective antibody responses to these vaccines, unlike live vaccines where responses are reduced.[1][2]
Evidence from Clinical Trials
In a randomized trial of 198 psoriasis patients, those on Cosentyx produced antibody titers to the inactivated tetanus-diphtheria toxoid vaccine comparable to placebo recipients (geometric mean fold rise of 11.1 vs. 12.4). Seroprotection rates exceeded 90% in both groups post-vaccination.[1] Similar results held for pneumococcal vaccine (23-valent polysaccharide), with protective antibody levels in over 70% of Cosentyx users.[3]
Live vs. Inactivated: Key Differences
Cosentyx suppresses responses to live vaccines like yellow fever (reduced neutralizing antibodies by 40-50%) due to its impact on T-cell immunity, prompting recommendations to avoid live vaccines during treatment.[2][4] Inactivated vaccines, however, rely less on IL-17 pathways and remain effective, aligning with FDA labeling.[1]
Practical Advice for Patients
Administer inactivated vaccines (e.g., flu, COVID-19, Tdap, pneumococcal) before starting Cosentyx if possible, or anytime during treatment without dose adjustments. No increased infection risk from these vaccines has been observed.[1][5] Consult providers for timing, especially if immunosuppressed.
Related Concerns: Boosters and Other Immunosuppressants
Booster responses to inactivated vaccines hold up on Cosentyx, per post-hoc analyses.[3] When combined with methotrexate, vaccine responses may dip slightly, but Cosentyx alone shows no such effect.[6] Monitor titers in high-risk patients.
Sources
[1]: Novartis Cosentyx Prescribing Information (FDA)
[2]: Bagel et al., J Drugs Dermatol (2019) – Vaccine response study
[3]: Kivitz et al., J Rheumatol (2017) – Pneumococcal vaccine trial
[4]: EMA Cosentyx Summary of Product Characteristics
[5]: CDC/ACIP Guidance on Immunosuppressants and Vaccines
[6]: Merola et al., J Am Acad Dermatol (2020) – Combo therapy analysis